Fecal Calprotectin Predicts Relapse and Histological Mucosal Healing in Ulcerative Colitis
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Fecal Calprotectin Predicts Relapse and Histological Mucosal Healing in Ulcerative Colitis. / Theede, Klaus; Holck, Susanne; Ibsen, Per; Kallemose, Thomas; Lassen, Inge Nordgaard; Nielsen, Anette Mertz.
I: Inflammatory Bowel Diseases, Bind 22, Nr. 5, 05.2016, s. 1042-1048.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Fecal Calprotectin Predicts Relapse and Histological Mucosal Healing in Ulcerative Colitis
AU - Theede, Klaus
AU - Holck, Susanne
AU - Ibsen, Per
AU - Kallemose, Thomas
AU - Lassen, Inge Nordgaard
AU - Nielsen, Anette Mertz
PY - 2016/5
Y1 - 2016/5
N2 - BACKGROUND: Mucosal healing in ulcerative colitis leads to a decreased need for medication and decreased risk of disease relapse and colectomy. Histological healing seems to improve the disease prognosis even further. An assessment of both endoscopic and histological mucosal healing requires endoscopy, and the need for a reliable noninvasive biomarker to predict disease relapse is obvious.METHODS: Seventy patients were included and followed up for 12 months. Inclusion criteria were a total Mayo score ≤1 and a Mayo endoscopic score = 0. The patients underwent sigmoidoscopy with rectal biopsies. Fecal calprotectin (FC) was measured 2 to 3 days before the sigmoidoscopy. The tissue samples were evaluated for neutrophilic inflammation. We aimed at testing the predictive performance of FC and histological inflammatory activity on disease relapse.RESULTS: A baseline FC level of more than 321 mg/kg predicted disease relapse at both the 6- and 12-month follow-ups. Histological inflammatory activity, C-reactive protein, or length of remission was not predictive of relapse. Of note, 11.8% of all patients had histological inflammatory activity despite endoscopic remission and were found to have a higher level of FC (236.5 versus 56 mg/kg, P = 0.02). A receiver operating characteristic analysis estimated a cutoff level of ≤40.5 mg/kg for FC (area under the curve, 0.755 and confidence interval 95%, 0.5895-0.9208) for predicting a histological inflammatory activity score of 0.CONCLUSIONS: FC measurements can be used to identify patients with increased risk of relapse after 6 and 12 months and to predict histological mucosal healing. Regular measurement of FC may alter disease monitoring and improve prognosis, and may decrease the need for endoscopy.
AB - BACKGROUND: Mucosal healing in ulcerative colitis leads to a decreased need for medication and decreased risk of disease relapse and colectomy. Histological healing seems to improve the disease prognosis even further. An assessment of both endoscopic and histological mucosal healing requires endoscopy, and the need for a reliable noninvasive biomarker to predict disease relapse is obvious.METHODS: Seventy patients were included and followed up for 12 months. Inclusion criteria were a total Mayo score ≤1 and a Mayo endoscopic score = 0. The patients underwent sigmoidoscopy with rectal biopsies. Fecal calprotectin (FC) was measured 2 to 3 days before the sigmoidoscopy. The tissue samples were evaluated for neutrophilic inflammation. We aimed at testing the predictive performance of FC and histological inflammatory activity on disease relapse.RESULTS: A baseline FC level of more than 321 mg/kg predicted disease relapse at both the 6- and 12-month follow-ups. Histological inflammatory activity, C-reactive protein, or length of remission was not predictive of relapse. Of note, 11.8% of all patients had histological inflammatory activity despite endoscopic remission and were found to have a higher level of FC (236.5 versus 56 mg/kg, P = 0.02). A receiver operating characteristic analysis estimated a cutoff level of ≤40.5 mg/kg for FC (area under the curve, 0.755 and confidence interval 95%, 0.5895-0.9208) for predicting a histological inflammatory activity score of 0.CONCLUSIONS: FC measurements can be used to identify patients with increased risk of relapse after 6 and 12 months and to predict histological mucosal healing. Regular measurement of FC may alter disease monitoring and improve prognosis, and may decrease the need for endoscopy.
KW - Adult
KW - Biomarkers
KW - Colitis, Ulcerative
KW - Feces
KW - Female
KW - Follow-Up Studies
KW - Humans
KW - Inflammation
KW - Leukocyte L1 Antigen Complex
KW - Male
KW - Mucous Membrane
KW - Prognosis
KW - Prospective Studies
KW - Recurrence
KW - Sigmoidoscopy
KW - Wound Healing
KW - Journal Article
KW - Observational Study
KW - Research Support, Non-U.S. Gov't
U2 - 10.1097/MIB.0000000000000736
DO - 10.1097/MIB.0000000000000736
M3 - Journal article
C2 - 26919460
VL - 22
SP - 1042
EP - 1048
JO - Inflammatory Bowel Diseases
JF - Inflammatory Bowel Diseases
SN - 1078-0998
IS - 5
ER -
ID: 176836682